LS@W supports Life Sciences startups through the Venture Challenge, Expert Classes and Value Center programs. Startups that have participated in (one or more) of these programs are listed as LS@W alumni. In addition startups that have received an NGI Pre-Seed Grant, which was part of LS@W from 2007 - 2012, are listed as LS@W alumni.
The Venture Challenge is the most successful program for startups in the Life Sciences and Medical Technology. More than 25 editions of the Venture Challenge have been organised helping startups in Therapeutics, Diagnostics, Medical Devices and Enabling Technologies. Startups that have participated in the Venture Challenge and still exist are listed.
Pre-Seed Grant Alumni
In the first years of LifeSciences@Work the NGI Pre-Seed Grant was part of the program. Startups that have received a Pre-Seed Grant via the LS@W program and still exist are listed.
To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.
Levels Dx is using activated immune cells as biomarkers to allow an accurate diagnosis of a bacterial infection in patients. The Rapid Diagnostic Tool (RDT) will provide accurate results within minutes and is portable.
We have developed a new, potent anticancer therapy with minimal side effects, as it has two levels of selectivity: a nanobody that directs a light-activatable drug to cancer cells, and light locally applied at the tumor to activate the drug.
MedicalVR’s PulmoVR innovation enables thoracic surgeons to cure patients with lung cancer by preventing the unnecessary removal of healthy lung tissue, resulting in a ‘lung-sparing surgical procedure’ for lung cancer.
We firmly believe that everybody has the basic human right to live without the limitations of disease. Therefore, we aim to provide patients with new treatment options that add true value and allow them to break free from those limitations.